ClinicalTrials.gg

Program

mosapride

Also written as “Mosapride Citrate Injection(high)”, “Mosapride Citrate Injection(low)” and “Reference mosapride citrate (GASMOTIN)”.

Its studies are mostly in Gastritis, led by 3 companies.

Furthest: phase 2, since Dec 19, 20133 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline10 open or runningphase 1since Dec 19, 2013Dec 19, 2013none ahead
IlDong Pharmaceutical10 open or runningphase 1since Mar 12, 2014Mar 12, 2014none ahead
Lunan Pharmaceutical Group11 open or runningphase 2since Jan 8, 2025Jan 8, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2013First study: phase 1 study in GastritisNew to GlaxoSmithKlineGlaxoSmithKline · NCT02201316 · 18 enrolled · India
  2. Mar 12, 2014IlDong Pharmaceutical's first study: phase 1 study in HealthyNew to IlDong PharmaceuticalIlDong Pharmaceutical · NCT02106130 · 40 enrolled · Korea, Republic of
  3. Jan 8, 2025Lunan Pharmaceutical Group's first study: phase 2 study in Postoperative Gastrointestinal DysfunctionNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06782594 · 150 planned · China

TargetBeta

“Serotonin 3 (5-HT3) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist”ChEMBL 37, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06782594Postoperative Gastrointestinal Dysfunction · China2RecruitingLunan Pharmaceutical GroupJun 2025150
NCT02106130Healthy · Korea, Republic of1CompletedIlDong PharmaceuticalJun 201340
NCT02201316Gastritis · India1CompletedGlaxoSmithKlineMar 18, 201418

How it is read

Names in the registry

  • “Mosapride Citrate Injection(high)”, 1 entry
  • “Mosapride Citrate Injection(low)”, 1 entry
  • “Reference mosapride citrate (GASMOTIN)”, 1 entry
  • “Mosapride citrate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.